Pfizer Calls for FDA Guidance to Address False and Misleading Biosimilar Ads

Taking issue with Amgen, Genentech and other reference product sponsors’ dissemination of misleading information on biosimilars, Pfizer is asking the US Food and Drug Administration (FDA) to take action with new guidance on what’s acceptable.